The department and the drugmaker said they would leverage an existing partnership to develop monoclonal antibodies for 2019-nCoV. A drug made by Gilead Sciences for Ebola is also being tested as a treatment for the rapidly spreading virus.
A greater willingness to embrace new technologies has made it easier to develop vaccines against the 2019-nCoV virus, while newer drugs have also shown signs of efficacy, experts said. More than 17,000 were confirmed infected worldwide as of Monday, the WHO reported.
This webinar will explore how a banking platform approach could be the resource for your company.